Pharmacokinetic characterization of a natural product–inspired novel MEK1 inhibitor E6201 in preclinical species

被引：0
|
作者：
Vipul Kumar
Edgar L. Schuck
Robert D. Pelletier
Nadia Farah
Krista B. Condon
Meng Ye
Christopher Rowbottom
Belinda M. King
Zhi-Yi Zhang
Philip L. Saxton
Y. Nancy Wong
机构：
[1] Cubist Pharmaceuticals,Non
[2] Biopharmaceutical Assessments CFU,clinical Drug Development
[3] Eisai Inc.,DMPK
[4] Eisai Inc.,Andover
[5] Biogen Idec,Development Quality Assurance
[6] 14 Cambridge Center,Department of Drug Metabolism and Pharmacokinetics
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词：
E6201; Pharmacokinetics; MEK1 inhibitor; Protein binding; CYP induction; CYP inhibition;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：229 / 237
页数：8
相关论文
共 30 条
  • [21] Phase 1 trial of MEK1 inhibitor E6201 plus dabrafenib in patients (pts) with BRAF V600-mutated metastatic melanoma (MM) with central nervous system (CNS) metastases (mets)
    Seetharam, Mahesh
    Dronca, Roxana
    Dudek, Arkadiusz Z.
    Nelson, Garth
    Block, Matthew
    Starling, Skylar
    Baskin, Amber
    Bradshaw, Renee
    Nelson, Courtney
    Andrews, Kylee
    Birgin, Alisha
    Watson, Cristina
    Yan, Yiyi
    Mahadevan, Daruka
    Markovic, Svetomir
    Myers, Tom
    Paradiso, Linda
    Babiker, Hani
    CANCER RESEARCH, 2024, 84 (07)
  • [22] Identification and Characterization of a Novel Chemotype MEK Inhibitor Able to Alter the Phosphorylation State of MEK1/2
    Yoshida, Takayuki
    Kakegawa, Junya
    Yamaguchi, Takayuki
    Hantani, Yoshiji
    Okajima, Nobuyuki
    Sakai, Toshiyuki
    Watanabe, Yoshihiro
    Nakamura, Motonao
    ONCOTARGET, 2012, 3 (12) : 1533 - 1545
  • [23] A novel preclinical model of RAF-independent MEK1 mutant tumors and its treatment with novel ATP competitive MEK inhibitor
    Hegedus, L.
    Okumus, Oe.
    Livingstone, E.
    Tovari, J.
    Bankfalvi, A.
    Aigner, C.
    Hegedus, B.
    ANNALS OF ONCOLOGY, 2019, 30 : 788 - 788
  • [24] Preclinical In vivo Evaluation of Efficacy, Pharmacokinetics, and Pharmacodynamics of a Novel MEK1/2 Kinase Inhibitor RO5068760 in Multiple Tumor Models
    Daouti, Sherif
    Higgins, Brian
    Kolinsky, Kenneth
    Packman, Kathryn
    Wang, Huisheng
    Rizzo, Christine
    Moliterni, John
    Huby, Nicholas
    Fotouhi, Nader
    Liu, Mei
    Goelzer, Petra
    Sandhu, Harpreet K.
    Li, Jia Kui
    Railkar, Aruna
    Heimbrook, David
    Niu, Huifeng
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (01) : 134 - 144
  • [25] The novel MEK1/2 inhibitor AZD6244 (ARRY-142886) inhibits the growth of melanomas harboring the BRAF V600E mutation in vitro and in vivo
    Haass, N. K.
    Smalley, K. S.
    Sproesser, K.
    Contractor, R.
    Herlyn, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 : S156 - S156
  • [26] Preclinical characterization of HBW-012-E, a novel, potent, selective, safe, and orally active KRAS G12D inhibitor with superior pharmacokinetic (PK) properties and anti-tumor efficacy
    Lee, Ning
    Li, Yingfu
    Liu, Guanfeng
    Li, Jiang
    Ren, Junfeng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] E6201, a Novel Kinase Inhibitor of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase-1 and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Kinase-1: In Vivo Effects on Cutaneous Inflammatory Responses by Topical Administration
    Muramoto, Kenzo
    Goto, Masaki
    Inoue, Yoko
    Ishii, Naoto
    Chiba, Ken-ichi
    Kuboi, Yoshikazu
    Omae, Takao
    Wang, Yuan J.
    Gusovsky, Fabian
    Shirota, Hiroshi
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 335 (01): : 23 - 31
  • [28] E6201 [(3S,4R,5Z,8S,9S,11E)-14-(Ethylamino)-8, 9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione], a Novel Kinase Inhibitor of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase (MEK)-1 and MEK Kinase-1: In Vitro Characterization of Its Anti-Inflammatory and Antihyperproliferative Activities
    Goto, Masaki
    Chow, Jesse
    Muramoto, Kenzo
    Chiba, Ken-ichi
    Yamamoto, Satoshi
    Fujita, Masanori
    Obaishi, Hiroshi
    Tai, Kenji
    Mizui, Yoshiharu
    Tanaka, Isao
    Young, Donna
    Yang, Hua
    Wang, Yuan J.
    Shirota, Hiroshi
    Gusovsky, Fabian
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2009, 331 (02): : 485 - 495
  • [29] Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study (vol 11, e0164646, 2016)
    Bekker, Pirow
    Dairaghi, Daniel
    Seitz, Lisa
    Leleti, Manmohan
    Wang, Yu
    Ertl, Linda
    Baumgart, Trageen
    Shugarts, Sarah
    Lohr, Lisa
    Dang, Ton
    Miao, Shichang
    Zeng, Yibin
    Fan, Pingchen
    Zhang, Penglie
    Johnson, Daniel
    Powers, Jay
    Jaen, Juan
    Charo, Israel
    Schall, Thomas J.
    PLOS ONE, 2019, 14 (01):
  • [30] Preclinical pharmacokinetic characterization of 2-(4-(4-(5-(2-phenyl-5-(trifluoromethyl) oxazole-4-carboxamido)-1H-benzo[d]imidazol-2-yl)phenyl) cyclohexyl) acetic acid, a novel DGAT-1 inhibitor
    Kwak, Eun-Young
    Im, So Hee
    Seo, Hyewon
    Cho, Woon-Ki
    Lee, Ye-Lim
    Woo, Jaechun
    Ahn, Sunjoo
    Ahn, Sung-Hoon
    Kwak, Hyun Jung
    Ahn, Jin Hee
    Bae, Myung Ae
    Song, Jin Sook
    XENOBIOTICA, 2014, 44 (05) : 465 - 471
123